GSK3B and myotonic dystrophy type 1: Our observations of altered MAPK and PI3K/Akt signaling in DM1 suggest dysregulation of pathways like GSK3β-CUGBP1 (Lutz et al., 2023), which may contribute to disease pathophysiology and provide potential avenues for future therapeutic strategies targeting both the molecular underpinnings and clinical progression of DM1.